Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

INDIANAPOLIS, Sept. 20 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has submitted an application with the European Medicines Agency (EMEA) for centralised review of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, for the first-line treatment of advanced non-small cell lung cancer (NSCLC).

ALIMTA is currently indicated in more than 85 countries as a second-line, single agent for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy, and is also indicated, in combination with cisplatin, for the treatment of patients with malignant pleural mesothelioma (MPM) whose disease is unresectable or who are otherwise not candidates for curative surgery.

The EMEA submission is based on a study which evaluated ALIMTA plus cisplatin versus GEMZAR(R) (gemcitabine HCl for injection) plus cisplatin. The study met its primary endpoint of non-inferiority relative to overall survival in a first-line NSCLC setting.

"As non-small cell lung cancer is the leading cause of cancer death worldwide, it is important that doctors have a range of treatments for this devastating illness," said Richard Gaynor, M.D., vice president of cancer research and global oncology platform leader for Lilly. "In this clinical study, ALIMTA plus cisplatin demonstrated similar efficacy to GEMZAR plus cisplatin, a widely used regimen for first-line NSCLC, while providing a more favorable toxicity profile and greater convenience. We look forward to the outcome of the EMEA review."

In September 2004, the EMEA approved ALIMTA as a single agent, second-line treatment for patients suffering from advanced NSCLC, as well as in combination with cisplatin
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Calif. , Aug. 28, 2014  In anticipation of ... infographic is being made available for the first time. ... Diego offers a snapshot of ... Highlighting everything from the latest employment statistics to ... made San Diego such a vital ...
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek,Pharmaceuticals Corporation ... preclinical animal data showing that the,administration of a ... on the survival of certain brain,cells following a ... the,repair of damaged DNA via the activation and ...
... study appearing in the March,22 New England Journal ... Healths National Institute of Arthritis and,Musculoskeletal and Skin ... gene and the inflammatory skin,condition vitiligo, as well ... is a chronic condition in which melanocytes (the ...
Cached Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:8/29/2014)... Auckland, NZ (PRWEB) August 29, 2014 ... of Greg Allen to Chief Executive Officer effective from ... Chief Technology Officer for Winscribe. , “During this time ... Winscribe than Greg Allen,” said Matthew Weavers, Winscribe’s Founder ... leader with a wealth of commercial, IT and management ...
(Date:8/28/2014)... 2014 Career Step, an online provider ... new video designed to help students and career seekers ... billing field. The video details what medical coders and ... professionals, and the education requirements for entering this field. ... often overlooked when people are considering a career in ...
(Date:8/28/2014)... FL (PRWEB) August 29, 2014 ... that brings pharmaceutical industry precision to the development ... zoning approval for its primary location in Sarasota ... and decisively with a total commitment to attracting ... forward to creating," says David Wright, President and ...
(Date:8/28/2014)... When David Gergen, President of ... Mark Brnovich, was asked to publicly support Mr. Brnovich ... Attorney General seat in the State of Arizona, Mr. ... of Cardinal Hall of Fame wide receiver Roy Green ... Mark Walczak. Green, Kennard and Walczak are members of ...
(Date:8/28/2014)... Farmington, New York (PRWEB) August 29, 2014 ... Autumn as they will be traveling around the country ... with a final show in November. The New Energy ... exhibit sharing their timber frame design and build expertise, ... addition, Drake Ambrosino , New Energy Works’ Mid-West ...
Breaking Medicine News(10 mins):Health News:Winscribe Names Greg Allen as CEO 2Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3
... ... recent launch of accounts on the popular social networking sites, Facebook, Twitter, and LinkedIn. ... Las Vegas, ... consultations, diagnoses, prescriptions, and doctors, excuses for work and school, expands its outreach to ...
... SEATTLE, Aug. 27 IDRI (Infectious Disease Research ... in Sudan to test its leishmaniasis vaccine candidate for ... complication of visceral leishmaniasis (VL) which is observed in ... predominantly affecting children. This trial reflects IDRI,s commitment to ...
... PRINCETON, N.J., Aug. 27 More than 160 ... are coming together at educational summits sponsored this fall by ... Continuing Education (CBCE). For the fifth year, the Inhibitor Education ... professionals and fellow patients to address pertinent topics such as ...
... rates similar to those with deceased donor transplant organs, ... People with kidney disease may do just as well ... from a deceased donor, new research has found. , ... 1,239 patients who had either received a kidney transplant ...
... Japan, Aug. 27 Hisamitsu Pharmaceutical Co., Inc. (TSE: ... completion of the tender offer for all outstanding shares of Noven ... price per share of $16.50. The subsequent offering period expired ... 2009 and was not extended. , , ...
... , MAPLE GROVE, Minn., Aug. 27 NeuroVasx, Inc., ... hemorrhagic and ischemic stroke, announced today that it has received approval ... Canada,s Therapeutic Products Directorate. In addition to Canadian regulatory approval, ... , Eric B. Timko, President and Chief Executive ...
Cached Medicine News:Health News:KoolDocs.com Increases Online Presence through Social Networking Premium Online Medical Consultation Service Now on Facebook, Twitter, and LinkedIn 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 2Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 11.0 mm and length 10 mm....
Medicine Products: